Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934774 | 0.91 | USP30 (0.59) | HPGDUSP30RECQLEPHX1PTPN2 | |
| SCHEMBL1780697 | 0.91 | USP30 (0.59) | HPGDUSP30RECQLEPHX1PTPN2 | |
| SCHEMBL14331976 | 0.91 | USP30 (0.59) | HPGDUSP30RECQLEPHX1PTPN2 | |
| SCHEMBL19026787 | 0.86 | GPR119 (0.52) | HPGDUSP30RECQLEPHX1USP2 | |
| SCHEMBL16415863 | 0.86 | EPHX1 (0.51) | HPGDUSP30RECQLEPHX1USP2 | |
| SCHEMBL4711418 | 0.85 | HPGD (0.55) | HPGDUSP30RECQLEPHX1USP2 | |
| SCHEMBL2904746 | 0.84 | EPHX1 (0.50) | HPGDUSP30RECQLEPHX1PTPN2 | |
| SCHEMBL3751065 | 0.84 | GPR119 (0.56) | HPGDGPR119 | |
| SCHEMBL19633473 | 0.83 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL26666918 | 0.83 | DDB1 (0.52) | HPGDUSP30RECQLEPHX1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-1660471-B1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1660471-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019194-A1 | DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LIMITED (GB) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | HPGD 1286/4885USP30 2905/4885RECQL 3381/4885 |
| US-20060281920-A1 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | MMP13, MMP3, MMP1 | HPGD 290/4885USP30 2739/4885RECQL 4329/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HPGD 987/4885USP30 2697/4885RECQL 3646/4885 |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | MMP3, MMP1, MMP13 | HPGD 74/4885USP30 1465/4885RECQL 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.